Pipeline
| Program | Therapeutic Area | Core Indications | Mode of Action |
|---|---|---|---|
| AKT-101 (optioned) | Immune-Stimulant | Prevention of secondary respiratory infections in dogs and cats | Oral bacterial lysate triggers non-specific immune response strengthening immune system against infections. |
| AKT-201 (internal) | Pain and Inflammation | Feline Gingivostomatitis + Equine Navicular Dx | Potent TRPV1 agonist defunctionalizes targeted nerves at site of injection interrupting pain signaling (non-opioid) |
| AKT-DEVA TLR7 Platform | Anti-Infective | Respiratory prophylaxis (dogs/cats) | TLR7 agonist (intranasal) |
| AKT-DEVB Vetendanib | Oncology | Aggressive tumors with metastatic potential | Triple Kinase Inhibitor |
| AKT-DEVC PhytoVet | Dermatology | Canine atopic dermatitis | PEA phytosome oral |
| AKT-DEVD Vextracorp | Device | Post-GDV and gastric surgery infections | Extracorporeal filtration device |
| AKT-DEVE VetOpal | Oncology, Pain & Dermatology | Aggressive tumors with metastatic potential | VHH bispecific nanobody (PD1/CTLA4) |
| AKT-DEVF Vetadipose | Metabolic | Obesity, Diabetes (dogs/cats) | Notch inhibitor |
Details available to interested investors under CDA (separate presentation)